Siponimod

---

Description

Siponimod is an oral medication approved by the FDA in 2019 for the treatment of adults with relapsing forms of multiple sclerosis (MS). It works by modulating the immune system, specifically by targeting the sphingosine 1-phosphate (S1P) receptor. By binding to these receptors, siponimod reduces the number of immune cells that can cross the blood-brain barrier and attack the myelin sheath, which protects nerve fibers in the brain and spinal cord. This mechanism of action helps to reduce the frequency and severity of MS relapses and slow the progression of disability.

Associated Diseases

• Relapsing-remitting multiple sclerosis (RRMS)
• Secondary progressive multiple sclerosis (SPMS)
• Active secondary progressive multiple sclerosis (SPMS)

Did you know?

Siponimod was originally developed as a treatment for rheumatoid arthritis but was found to be more effective in treating MS.